Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Markéta Marková Šťastná"'
Autor:
Hana Klamová, Kateřina Machová Poláková, Jan Mužík, Zdeněk Ráčil, Daniela Žáčková, Kateřina Steinerová, Michal Karas, Edgar Faber, Eva Demečková, Zuzana Michalovičová‐Sninská, Jaroslava Voglová, Ľudmila Demitrovičová, Eva Mikušková, Elena Tóthová, Juraj Chudej, Imrich Markuljak, Eduard Cmunt, Jana Moravcová, Dana Dvořáková, Kyra Michalová, Marie Jarošová, Markéta Marková Šťastná, Petr Cetkovský, Ladislav DuŠek, Vladimír Koza, Marek Trněný, Karel Indrák
Publikováno v:
Cancer Medicine, Vol 2, Iss 2, Pp 216-225 (2013)
Abstract We evaluated responses to the treatment and long‐term outcomes of chronic myeloid leukemia patients treated with imatinib as first‐line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors
Externí odkaz:
https://doaj.org/article/3352c3f69ea544aab068556ac3c96068
Autor:
Marek Trněný, Michal Karas, Imrich Markuljak, Kateřina Machová Poláková, Jaroslava Voglová, Karel Indrak, Jan Mužík, Kyra Michalova, Marie Jarošová, Markéta Marková Šťastná, Vladimir Koza, Zdeněk Ráčil, Kateřina Steinerová, Elena Tóthová, Ľudmila Demitrovičová, Eva Mikuskova, Eva Demečková, Eduard Cmunt, Edgar Faber, Daniela Žáčková, Ladislav Dušek, Dana Dvořáková, Zuzana Michalovičová-Sninská, Hana Klamova, Juraj Chudej, Petr Cetkovský, Jana Moravcová
Publikováno v:
Cancer Medicine. 2:216-225
We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1de8c83512329e9d750d3b06a947baec
https://doi.org/10.1002/cam4.59
https://doi.org/10.1002/cam4.59
Autor:
Karin Malickova, Hana Benáková, Markéta Marková Šťastná, Václava Adámková, Tomáš Zima, Helena Brodska
Publikováno v:
Clinical and experimental medicine. 13(3)
Procalcitonin (PCT) levels can distinguish between infectious and non-infectious systemic inflammatory response. However, there are some differences between Gram-negative (G−), Gram-positive (G+), and fungal bloodstream infections, particularly in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::506f39e97a2839b0bd3f8eb5c5b2f2fc
https://pubmed.ncbi.nlm.nih.gov/22644264
https://pubmed.ncbi.nlm.nih.gov/22644264
Autor:
Ales Tichy, Sylwia Kabacik, Grainne O'Brien, Jaroslav Pejchal, Zuzana Sinkorova, Adela Kmochova, Igor Sirak, Andrea Malkova, Caterina Gomila Beltran, Juan Ramon Gonzalez, Jakub Grepl, Matthaeus Majewski, Elizabeth Ainsbury, Lenka Zarybnicka, Jana Vachelova, Alzbeta Zavrelova, Marie Davidkova, Marketa Markova Stastna, Michael Abend, Eileen Pernot, Elisabeth Cardis, Christophe Badie
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0193412 (2018)
The increasing risk of acute large-scale radiological/nuclear exposures of population underlines the necessity of developing new, rapid and high throughput biodosimetric tools for estimation of received dose and initial triage. We aimed to compare th
Externí odkaz:
https://doaj.org/article/ecfaeb687a454bffa8ba5b28ad9633ec